Descargar la presentación
La descarga está en progreso. Por favor, espere
Publicada porAmaranta Cato Modificado hace 10 años
1
ARRITMIAS Ignacio Fernández Lozano. Javier Alzueta.
2
FA
3
402 PT
4
1.376 PT
5
5.700 PT CHADS FAPx 1,8 FAPn 2
6
627 PT
7
End pointPlacebo (%/y)Dronedarone (%/y) HR (95% CI)p Stroke1.791.190.66 (0.46- 0.96) 0.027 Stroke or TIA2.051.370.67 (0.47- 0.94) 0.020 Fatal stroke0.540.360.67 (0.34- 1.32) 0.247 Stroke, ACS, or CV death5.523.800.68 (0.55- 0.84) <0.001 Stroke, ACS, or all-cause death6.705.060.75 (0.62- 0.90) 0.002 4.628 PT
8
Purpose The objective of this study is to compare the efficacy and safety of dronedarone to that of amiodarone for the treatment of patients with atrial fibrillation. ArmsAssigned Interventions 1: ExperimentalDrug: dronedarone (SR33589) 400mg bid 2: Active ComparatorDrug: amiodarone 600mg daily for 28 days, then 200mg daily Ages Eligible for Study: 21 Years and older Genders Eligible for Study: Both Accepts Healthy Volunteers: No 504 PT
9
112 PT
13
SINCOPE
15
Estratificación de riesgo
17
504 PT
19
Incidencia de Muerte súbita Myerburg RJ. Circulation.1998;97:1514-1521. GROUP >2 factores de riesgo Pacientes con enfermedad coronaria Pacientes con FE <35%, e ICC Pacientes con PCR previa Pacientes con IAM FE deprimida y TV Población global 300,000200,000100,0000 Nº. De MS anual 30 25 20 10 5 0 Incidencia de MS (% grupo)
20
High energy implant rates pmp Source: Eucomed
22
490 PT
23
651 PT
25
206 PT
27
45 PT
28
7.001 PT
Presentaciones similares
© 2024 SlidePlayer.es Inc.
All rights reserved.